Seeking Alpha
05 Oct 2026, 18:30 UTC · 2h ago
Impact · against what's priced in
Compugen provides positive clinical updates on COM701 and its UNIGEN platform, which may serve as a catalyst for sentiment. The overall impact is modestly positive based on the trial progress and platform advancements.
No priced-in read yet
Which stocks this story touches
More positive than 76% of ticker scores this week
The company is providing positive updates on its COM701 clinical trial and platform advancements.
Continue reading
5 related stories
The updates on the COM701 ovarian cancer trial and the MAIA trial preview provide positive momentum for the company's pipeline and platform capabilities.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
5h ago
+0.0%
Price flat so far
$2.31 vs $2.31 close before publication (Oct 2) · not market-adjusted
CGEN chart →
